Search

Your search keyword '"Laus, G."' showing total 48 results

Search Constraints

Start Over You searched for: Author "Laus, G." Remove constraint Author: "Laus, G." Search Limiters Full Text Remove constraint Search Limiters: Full Text
48 results on '"Laus, G."'

Search Results

1. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

3. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

13. Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

14. P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases

15. Phase-out-compliant fluorosurfactants

16. Dietary restraint, life satisfaction and self-discrepancy by gender in university students

17. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

18. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)

26. Inhibition of NF-κB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes.

28. 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC).

29. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors

30. Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.

31. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.

32. Synthesis and crystal structures of two 1,3-di(alk-yloxy)-2-(methyl-sulfan-yl)imidazolium tetra-fluorido-borates.

33. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.

34. Synthesis and crystal structures of 2-bromo-1,3-di-methyl-imidazolium iodides.

35. ( E )-2,6-Di-bromo-4-{2-[1-(1 H ,1 H ,2 H ,2 H -perfluoro-oct-yl)pyridinium-4-yl]ethen-yl}phenolate methanol disolvate, a fluoro-ponytailed solvatochromic dye.

36. Crystal structure of bis-(1,3-di-meth-oxy-imidazolin-2-yl-idene)silver(I) hexa-fluorido-phosphate, N-heterocyclic carbene (NHC) complex.

37. Crystal structure of 1-(1-methyl-1H-imidazol-2-yl)-4-phenyl-1H-1,2,3-triazole dihydrate.

38. Crystal structure of 3-bromo-2-hy-droxy-benzoic acid.

39. Crystal structure of 1-[2-(di-ethyl-aza-n-ium-yl)eth-yl]-3-methyl-imidazolium tetra-chlorido-cuprate(II).

40. Crystal structure of 3-bromo-4-di-methyl-amino-1-methyl-1,2,4-triazol-5(4H)-one.

41. Crystal Structures of New Ammonium 5-Aminotetrazolates.

42. Draft genome sequence analysis of a Pseudomonas putida W15Oct28 strain with antagonistic activity to Gram-positive and Pseudomonas sp. pathogens.

43. Crystal structure of 4-amino-1-benzyl-1,2,4-triazolin-5-one.

44. Mössbauer spectroscopy and X-ray diffraction study of Fe-labeled tetrachloroferrate(III)-based magnetic ionic liquids.

45. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.

46. Inhibition of NF-kappaB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes.

47. Mechanistic diversity of the van Leusen reaction applied to 6-ketomorphinans and synthetic potential of the resulting acrylonitrile substructures.

48. Reconsidering the energetics of ribonuclease catalysed RNA hydrolysis.

Catalog

Books, media, physical & digital resources